Brief: Elicera Therapeutics Q4 Operating Loss Narrows To SEK 2.14 Mln
Jan 25 (Reuters) - Elicera Therapeutics AB ELIC.ST :
* ELICERA THERAPEUTICS AB (PUBL) INTERIM REPORT 1 JANUARY -
31
DECEMBER 2021
* Q4 OPERATING LOSS TOTALED SEK -2,142,267 (-2,596,526)
* PROPOSED DIVIDEND OF SEK 0.00 PER SHARE (0.00 FOR
PRECEDING
YEAR)
* Q4 LOSS FOR PERIOD TOTALED SEK -2,142,267 (-2,596,256)
Source text for Eikon: ID:nWkr204zTr
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Nomination Committee Proposes Margareth Jorvid As Chair Of Elicera Board
Brief: Elicera Therapeutics Carries Out Rights Issue Of About SEK 73 Mln
Sweden's Elicera Therapeutics Q1 loss narrows, reports positive clinical progress
Brief: Elicera Therapeutics Q1 Operating Loss SEK 5.1 Mln
Brief: Elicera Therapeutics Gets Notice Of Allowance For Japanease Patent